Maria Q. Baggstrom, MD, Saiama N. Waqar, MD, Ananth K

Slides:



Advertisements
Similar presentations
Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Advertisements

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
A Hole in the Heart Journal of Thoracic Oncology
Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.
The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.
Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
SC17.02 Lung Cancer in China: Challenges and Perspectives
ALK FISH and IHC: You Cannot Have One without the Other
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.
Biostatistics Primer: What a Clinician Ought to Know—Prognostic and Predictive Factors  Lorinda Simms, MSc, P Stat, Helen Barraclough, MSc, Ramaswamy.
Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC
Irinotecan-Cisplatin Therapy for Patients with Extensive-Stage Small Cell Lung Cancer: Use Patterns among American Medical Oncologists 2000–2006  Mark.
Electronic Updates for JTO Readers
Hedgehog Signaling Pathway and Lung Cancer
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.
Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients  Jean-Louis Pujol, MD, Patrick.
Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer  Daniel Morgensztern, MD, Saiama.
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Frank Detterbeck, MD  Journal of Thoracic Oncology 
Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP 
Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.
The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials  Krista.
Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer  Masahiko Harada,
Jeffrey Bradley, MD, Issam El Naqa, PhD  Journal of Thoracic Oncology 
Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database  Laura C. Caprario, MD, MS,
Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.
Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature  Caicun Zhou, MD, PhD, Luan Di Yao, MD 
A Hole in the Heart Journal of Thoracic Oncology
Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E
Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q
Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.
Radiation-Induced Myonecrosis Presenting as a Subcutaneous Mass After Combined Modality Therapy for Non-small Cell Lung Cancer  Vamsidhar Velcheti, MD,
ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers  Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.
Mitotic Inhibitors Journal of Thoracic Oncology
Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?  Charles Lim, MD, Mike Sung, BSc,
Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non- small Cell Lung Cancer  Eric Duncavage, MD, Boone Goodgame, MD, Ananth Sezhiyan,
Mirror Mirror on the Wall, Who Is the Fairest of Them All
Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non- small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis.
Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey  Daniel Morgensztern, MD, Shean Huey Ng,
Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.
Jennifer S. Temel, MD, William F. Pirl, MD, Christopher J
Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.
Pulmonary Metastasectomy in Breast Cancer
T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)
Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base  Susan E. Combs, MA, Jacquelyn.
Jie Huang, Juan Peng, Linlang Guo, MD, PhD 
A Phase II Study of Irinotecan and Carboplatin in Advanced Non-small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report  Giancarlo A. Pillot,
Saiama N. Waqar, M. B. B. S. , MSCI, Philip D
Survival after Trimodality Treatment for Superior Sulcus and Central T4 Non-small Cell Lung Cancer  Paul De Leyn, MD, PhD, Johan Vansteenkiste, MD, PhD,
Genetic Changes in Squamous Cell Lung Cancer: A Review
Ethnic Differences in the Management of Lung Cancer in New Zealand
BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced,
A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104  Ramaswamy Govindan, MD, Xiaofei.
European Lung Cancer Conference (ELCC) 2016 Organisation
Annemarie Becker, MD, PhD, Atie van Wijk, RN, Egbert F
Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery  Raja M. Flores, MD  The Journal.
Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.
A Review of First-Line Treatment for Small-cell Lung Cancer
Mark A. Socinski, MD  Journal of Thoracic Oncology 
Robert Comis, MD, The Passing of a “Lung Man”
Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.
Presentation transcript:

Barriers to Enrollment in Non-small Cell Lung Cancer Therapeutic Clinical Trials  Maria Q. Baggstrom, MD, Saiama N. Waqar, MD, Ananth K. Sezhiyan, BS, Eve Gilstrap, RN, Feng Gao, PhD, Daniel Morgensztern, MD, Ramaswamy Govindan, MD  Journal of Thoracic Oncology  Volume 6, Issue 1, Pages 98-102 (January 2011) DOI: 10.1097/JTO.0b013e3181fb50d8 Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Flow diagram of patients enrolled on a clinical trial. Journal of Thoracic Oncology 2011 6, 98-102DOI: (10.1097/JTO.0b013e3181fb50d8) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.